vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
Syndax Pharmaceuticals Inc is the larger business by last-quarter revenue ($68.5M vs $48.4M, roughly 1.4× First Foundation Inc.). First Foundation Inc. runs the higher net margin — -97.9% vs -99.3%, a 1.4% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 421.7%).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
FFWM vs SNDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $68.5M |
| Net Profit | $-8.0M | $-68.0M |
| Gross Margin | — | — |
| Operating Margin | -97.5% | -91.3% |
| Net Margin | -97.9% | -99.3% |
| Revenue YoY | 421.7% | 791.7% |
| Net Profit YoY | 43.0% | 27.8% |
| EPS (diluted) | $-0.09 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $68.5M | ||
| Q3 25 | $63.6M | $45.9M | ||
| Q2 25 | $51.4M | $38.0M | ||
| Q1 25 | $71.4M | $20.0M | ||
| Q4 24 | $9.3M | — | ||
| Q3 24 | $9.2M | $12.5M | ||
| Q2 24 | $57.5M | — | ||
| Q1 24 | $51.1M | $0 |
| Q4 25 | $-8.0M | $-68.0M | ||
| Q3 25 | $-146.3M | $-60.7M | ||
| Q2 25 | $-7.7M | $-71.8M | ||
| Q1 25 | $6.9M | $-84.8M | ||
| Q4 24 | $-14.1M | — | ||
| Q3 24 | $-82.2M | $-84.1M | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | $793.0K | $-72.4M |
| Q4 25 | -97.5% | -91.3% | ||
| Q3 25 | -92.7% | -125.2% | ||
| Q2 25 | -21.1% | -182.7% | ||
| Q1 25 | 8.8% | -417.9% | ||
| Q4 24 | -247.7% | — | ||
| Q3 24 | -1276.7% | -716.6% | ||
| Q2 24 | 4.6% | — | ||
| Q1 24 | -0.2% | — |
| Q4 25 | -97.9% | -99.3% | ||
| Q3 25 | -230.1% | -132.4% | ||
| Q2 25 | -15.0% | -189.3% | ||
| Q1 25 | 9.7% | -423.3% | ||
| Q4 24 | -152.2% | — | ||
| Q3 24 | -896.9% | -673.0% | ||
| Q2 24 | 5.4% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | $-0.09 | $-0.78 | ||
| Q3 25 | $-1.78 | $-0.70 | ||
| Q2 25 | $-0.09 | $-0.83 | ||
| Q1 25 | $0.08 | $-0.98 | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-1.23 | $-0.98 | ||
| Q2 24 | $0.05 | — | ||
| Q1 24 | $0.01 | $-0.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $912.6M | $64.6M |
| Total Assets | $11.9B | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $394.1M | ||
| Q3 25 | $1.7B | $436.0M | ||
| Q2 25 | $1.1B | $455.2M | ||
| Q1 25 | $1.0B | $512.2M | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | $389.6M | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.6B | $434.6M |
| Q4 25 | $912.6M | $64.6M | ||
| Q3 25 | $917.9M | $115.4M | ||
| Q2 25 | $1.1B | $157.4M | ||
| Q1 25 | $1.1B | $215.1M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | $366.4M | ||
| Q2 24 | $933.2M | — | ||
| Q1 24 | $928.7M | $491.9M |
| Q4 25 | $11.9B | $529.7M | ||
| Q3 25 | $11.9B | $551.8M | ||
| Q2 25 | $11.6B | $596.1M | ||
| Q1 25 | $12.6B | $640.7M | ||
| Q4 24 | $12.6B | — | ||
| Q3 24 | $13.4B | $425.8M | ||
| Q2 24 | $13.7B | — | ||
| Q1 24 | $13.6B | $543.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $-69.5M |
| Free Cash FlowOCF − Capex | $-35.2M | — |
| FCF MarginFCF / Revenue | -72.8% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $-69.5M | ||
| Q3 25 | $9.2M | $-70.5M | ||
| Q2 25 | $-16.3M | $-87.8M | ||
| Q1 25 | $-552.0K | $-95.2M | ||
| Q4 24 | $-8.7M | — | ||
| Q3 24 | $14.2M | $-62.3M | ||
| Q2 24 | $-9.1M | — | ||
| Q1 24 | $7.2M | $-83.5M |
| Q4 25 | $-35.2M | — | ||
| Q3 25 | $8.6M | — | ||
| Q2 25 | $-16.7M | — | ||
| Q1 25 | $-2.5M | — | ||
| Q4 24 | $-11.4M | — | ||
| Q3 24 | $13.4M | — | ||
| Q2 24 | $-9.4M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | -72.8% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | -32.4% | — | ||
| Q1 25 | -3.5% | — | ||
| Q4 24 | -123.5% | — | ||
| Q3 24 | 146.2% | — | ||
| Q2 24 | -16.3% | — | ||
| Q1 24 | 11.6% | — |
| Q4 25 | 6.9% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 9.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
